Gabriela Calamante

Dr. Gabriela Calamante

Inst. de Biotecnología IABIMO UEDD INTA-CONICET, INTA, Buenos Aires, Argentina
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Viruses
Verified
Journal Article
Open access
PDF file
MHMaría Pía Holgado
María Pía Holgado
JFJuliana Falivene
Juliana Falivene
CMCynthia Maeto
Cynthia Maeto
MAMicaela Amigo
Micaela Amigo
MPMaria Fernanda Pascutti
Maria Fernanda Pascutti
MHMaría Pía Holgado
María Pía Holgado
MVA is an attenuated vector that still retains immunomodulatory genes. We have previously reported its optimization after deleting the C12L gene, coding for the IL-18 binding-protein. Here, we analyzed the immunogenicity of MVA vectors harboring the simultaneous deletion of A44L, related to steroid synthesis and A46R, a TLR-signaling inhibitor (MVAΔA44L-A46R); or also including a deletion of C12L (MVAΔC12L/ΔA44L-A46R). The absence of biological activities of the deleted genes in the MVA vectors was demonstrated. Adaptive T-cell responses against VACV epitopes, evaluated in spleen and draining lymph-nodes of C57Bl/6 mice at acute/memory phases, were of higher magnitude in those animals that received deleted MVAs compared to MVAwt. MVAΔC12L/ΔA44L-A46R generated cellular specific memory responses of higher quality characterized by bifunctionality (CD107a/b+/IFN-γ+) and proliferation capacity. Deletion of selected genes from MVA generated innate immune responses with higher levels of determining cytokines related to T-cell response generation, such as IL-12, IFN-γ, as well as IL-1β and IFN-β. This study describes for the first time that simultaneous deletion of the A44L, A46R and C12L genes from MVA improved its immunogenicity by enhancing the host adaptive and innate immune responses, suggesting that this approach comprises an appropriate strategy to increase the MVA vaccine potential.

23 September 2020 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
MMMaria Paula Morelli
Maria Paula Morelli
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
JPJoaquín Miguel Pellegrini
Joaquín Miguel Pellegrini
NANicolás Oscar Amiano
Nicolás Oscar Amiano
NTNancy Liliana Tateosian
Nancy Liliana Tateosian
VGVerónica García
Verónica García
Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of death worldwide. The Modified Vaccinia Ankara (MVA) vaccine vector expressing the mycobacterial antigen 85A (MVA85A) was demonstrated to be safe, although it did not improve BCG efficacy, denoting the need to search for improved tuberculosis vaccines. In this work, we investigated the effect of IL-12 DNA -as an adjuvant- on an Ag85A DNA prime/MVA85A boost vaccination regimen. We evaluated the immune response profile elicited in mice and the protection conferred against intratracheal Mtb H37Rv challenge. We observed that the immunization scheme including DNA-A85A+DNA-IL-12/MVA85A induced a strong IFN-γ production to Ag85A in vitro, with a significant expansion of IFN-γ+CD4+ and IFN-γ+CD8+ anti-Ag85A lymphocytes. Furthermore, we also detected a significant increase in the proportion of specific CD8+CD107+ T cells against Ag85A. Additionally, inclusion of IL-12 DNA in the DNA-A85A/MVA85A vaccine scheme induced a marked augment in anti-Ag85A IgG levels. Interestingly, after 30 days of infection with Mtb H37Rv, DNA-A85A+DNA-IL-12/MVA85A vaccinated mice displayed a significant reduction in lung bacterial burden. Together, our findings suggest that IL-12 DNA might be useful as a molecular adjuvant in an Ag85A DNA/MVA prime-boost vaccine against Mtb infection.

3 November 2016 in Viral Immunology
Verified
Journal Article
Closed access
Maria Paula Del Médico ZajacMaria Paula Del Médico Zajac
Maria Paula Del Médico Zajac
FZFlavia Adriana Zanetti
Flavia Adriana Zanetti
MEMaría Soledad Esusy
María Soledad Esusy
CFCarlos Rodolfo Federico
Carlos Rodolfo Federico
OZOsvaldo Zabal
Osvaldo Zabal
Gabriela CalamanteGabriela Calamante
Gabriela Calamante
In this study, we evaluated the immunogenicity and efficacy of mucosal delivery of a recombinant modified vaccinia Ankara virus (MVA) expressing the secreted version of bovine herpesvirus type 1 (BoHV-1) glycoprotein D (MVA-gDs) without addition of adjuvant in two animal models. First, we demonstrated the capability of MVA-gDs of inducing both local and systemic anti-gD humoral immune response after intranasal immunization of mice. Then, we confirmed that two doses of MVA-gDs administered intranasally to rabbits induced systemic anti-gD antibodies and conferred protection against BoHV-1 challenge. Our results show the potential of using MVA as a vector for the rational design of veterinary vaccines capable of inducing specific and protective immune responses both at local and systemic level.

1 January 2017 in Vaccine
Verified
Journal Article
Open access
MRMatías Richetta
Matías Richetta
EGEvangelina Gómez
Evangelina Gómez
MLMaría Soledad Lucero
María Soledad Lucero
SZSilvina Chimeno Zoth
Silvina Chimeno Zoth
MGMaría José Gravisaco
María José Gravisaco
ABAnalía Berinstein
Analía Berinstein
Different immunogens such as subunit, DNA or live viral-vectored vaccines against Infectious Bursal Disease virus (IBDV) have been evaluated in the last years. However, the heterologous prime-boost approach using recombinant modified vaccinia Ankara virus (rMVA), which has shown promising results in both mammals and chickens, has not been tried against this pathogen yet. IBD is a highly contagious and immunosuppressive disease of poultry that affects mainly young chicks. It is caused by IBDV, a double-stranded RNA virus carrying its main antigenic epitopes on the capsid protein VP2. Our objective was to evaluate the immune response elicited by two heterologous prime-boost schemes combining an rMVA carrying the VP2 mature gene (rVP2) and a recombinant VP2 protein produced in Nicotiana benthamiana (pVP2), and to compare them with the performance of the homologous pVP2-pVP2 scheme usually used in our laboratory. The SPF chickens immunized with the three evaluated schemes elicited significantly higher anti-VP2 antibody titers (p<0.001) and seroneutralizing titers (p<0.05) and had less T-cell infiltration (p<0.001), histological damage (p<0.001) and IBDV particles (p<0.001) in their bursae of Fabricius when compared with control groups. No significant differences were found between both heterologous schemes and the homologous one. However, the rVP2-pVP2 scheme showed significantly higher anti-VP2 antibody titers than pVP2-rVP2 and a similar tendency was found in the seroneutralization assay. Conversely, pVP2-rVP2 had the best performance when evaluated through bursal parameters despite having a less potent humoral immune response. These findings suggest that the order in which rVP2 and pVP2 are combined can influence the immune response obtained. Besides, the lack of a strong humoral immune response did not lessen the ability to protect from IBDV challenge. Therefore, further research is needed to evaluate the mechanisms by which these immunogens are working in order to define the combination that performs better against IBDV.

1 January 2014 in Brazilian Journal of Microbiology
Verified
Journal Article
Open access
PDF file
FZFlavia Adriana Zanetti
Flavia Adriana Zanetti
MGMaría Daniela Conte Grand
María Daniela Conte Grand
RMRomina Cristina Mitarotonda
Romina Cristina Mitarotonda
OTOscar Alberto Taboga
Oscar Alberto Taboga
Gabriela CalamanteGabriela Calamante
Gabriela Calamante
Canarypox viruses (CNPV) carrying the coding sequence of VP2 protein from infectious bursal disease virus (IBDV) were obtained. These viruses were able to express VP2 protein in vitro and to induce IBDV-neutralizing antibodies when inoculated in specific pathogen-free chickens demonstrating that CNPV platform is usefulness to develop immunogens for chickens.